Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591764 | 0.87 | TGFBR1 (0.73) | TGFBR1 | |
| SCHEMBL373185 | 0.84 | TGFBR1 (0.73) | TGFBR1 | |
| SCHEMBL3601420 | 0.82 | TGFBR1 (0.67) | TGFBR1 | |
| SCHEMBL372655 | 0.82 | TGFBR1 (1.00) | TGFBR1 | |
| SCHEMBL372749 | 0.81 | TGFBR1 (0.74) | TGFBR1 | |
| SCHEMBL3608473 | 0.81 | TGFBR1 (0.74) | TGFBR1 | |
| SCHEMBL373738 | 0.81 | TGFBR1 (1.00) | TGFBR1 | |
| SCHEMBL373419 | 0.79 | TGFBR1 (1.00) | TGFBR1 | |
| SCHEMBL3599651 | 0.78 | TGFBR1 (0.84) | TGFBR1 | |
| SCHEMBL388530 | 0.77 | TGFBR1 (1.00) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056505-A1 | Substituted Pyrazalones | BIOGEN IDEC MA INC. | 2010-03-04 | — | — | US | claimed |
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2010-02-04 | — | — | US | claimed |
| US-7601722-B2 | Aryl sulfamide derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | claimed |
| EP-1971594-A2 | SUBSTITUTED PYRAZALONES | Biogen Idec MA Inc. (US) | 2008-09-24 | — | — | EP | claimed |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-10 | — | — | US | claimed |
| WO-2007059359-A2 | SUBSTITUTED PYRAZALONES | BIOGEN IDEC MA INC. (US) | 2007-05-24 | — | — | WO | claimed |
| US-20100056505-A1 | Substituted Pyrazalones | BIOGEN IDEC MA INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-7601722-B2 | Aryl sulfamide derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | TGFBR1 2009/4885 |
| US-20100056505-A1 | Substituted Pyrazalones | ACVR1, ACVRL1, TGFBR1 | TGFBR1 3/4885 |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | TGFBR1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.